Skip to main content
Home
FULL MENU Close Menu
Home
Home

Mary Ellen Schneider

News

U.S. reports first death from COVID-19, possible outbreak at long-term care facility

Author:
Mary Ellen Schneider
Publish date: February 29, 2020

Health officials in Washington state said they are investigating a long-term care facility with two presumptive positive cases of COVID-19 and...

  • Read More

Video

Experts break down latest CAR T-cell advances in lymphoma

Author:
Mary Ellen Schneider
Publish date: January 22, 2020

ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...

  • Read More

News

Hematology News welcomes Dr. Ify Osunkwo as editor in chief

Author:
Mary Ellen Schneider
Publish date: January 2, 2020

Dr. Osunkwo is a specialist in sickle cell disease and the director of the sickle cell program at Levine Cancer Institute in Charlotte, N.C.

  • Read More

News

Think twice: Choosing Wisely recommendations on testing to avoid in pediatric hematology

Author:
Mary Ellen Schneider
Publish date: December 10, 2019

ORLANDO – The list, which was released by ASH and the American Society of Pediatric Hematology/Oncology, includes five unnecessary tests or...

  • Read More

News

Myeloma patients over age 70 can benefit from auto-HC transplant

Author:
Mary Ellen Schneider
Publish date: December 7, 2019

ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.

  • Read More

News

FDA approves treatment for sickle cell pain crises

Author:
Mary Ellen Schneider
Publish date: November 15, 2019

Crizanlizumab-tmca (Adakveo) is approved for patients with sickle cell disease who are aged 16 years and older.

  • Read More

News

FDA approves anemia treatment for transfusion-dependent beta thalassemia patients

Author:
Mary Ellen Schneider
Publish date: November 8, 2019

Luspatercept-aamt (Reblozyl) is approved for adults with beta thalassemia who require regular red blood cell transfusions.

  • Read More

News

ASCO to award $50,000 young investigator grant to study MCL

Author:
Mary Ellen Schneider
Publish date: October 23, 2019

The award is a 1-year grant of $50,000 to pursue clinical research on mantle cell lymphoma.

  • Read More

News

Hematopoietic cell transplant offers realistic cure in secondary AML

Author:
Mary Ellen Schneider
Publish date: October 23, 2019

The observational trial showed that survival was significantly higher with transplant than with chemotherapy consolidation therapy in patients...

  • Read More

News

FDA gives nod to earlier use of Nplate in adults with ITP

Author:
Mary Ellen Schneider
Publish date: October 18, 2019

The drug is now indicated for newly diagnosed and persistent adult patients with immune thrombocytopenia and an insufficient response to other...

  • Read More

News

Translucent particles found in Hemlibra

Author:
Mary Ellen Schneider
Publish date: October 11, 2019

Genentech says the benefit-risk profile of the hemophilia A product is unchanged, and it will continue to be distributed.

  • Read More

News

Progressive myeloma after induction? Go straight to transplant

Author:
Mary Ellen Schneider
Publish date: September 6, 2019

The study did not find a survival advantage for patients who had salvage therapy to deepen their responses before moving on to transplant.

  • Read More

News

Calquence earns breakthrough designation for CLL monotherapy

Author:
Mary Ellen Schneider
Publish date: August 27, 2019

The Bruton tyrosine kinase inhibitor is already approved for the treatment of adults with mantle cell lymphoma who have received at least one...

  • Read More

News

Low-dose radiation therapy looks effective in hard-to-treat MCL

Author:
Mary Ellen Schneider
Publish date: August 7, 2019

The treatment approach can be used safely with concurrent chemotherapy.

  • Read More

News

ABIM rolls out shorter, tailored MOC exams in oncology

Author:
Mary Ellen Schneider
Publish date: July 23, 2019

The new pathway allows oncologists to choose a focused exam in hematologic malignancies, breast cancer, or general oncology every 2 years,...

  • Read More

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close